预约演示
更新于：2025-05-24
Risperidone
利培酮
更新于：2025-05-24
概要
基本信息
简介利培酮（商品名为：RISPERDAL®）是一种非典型抗精神病药物。该药品由强生公司开发，于1993年12月29日获得美国食品药品监督管理局（FDA）批准。利培酮用于治疗精神分裂症，以及与双相I型障碍相关的急性躁狂或混合发作，可作为单药治疗或与锂或丙戊酸辅助治疗。此外，该药品还被批准用于治疗与自闭症谱系障碍相关的烦躁情绪。该药品通过抑制多巴胺2型（D2）和5-羟色胺2型（5HT2）受体结合起作用，这被认为是其治疗精神分裂症的疗效贡献之一。利培酮一般耐受性较好，但可能会引起体重增加、嗜睡和锥体外系症状等副作用。 |
药物类型 小分子化药 |
别名 Risperdal OD、Risperidone (JP17/USP/INN)、Risperidone for Depot Suspension + [43] |
作用方式 拮抗剂 |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27FN4O2 |
InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N |
CAS号106266-06-2 |
关联
513
项与 利培酮 相关的临床试验NCT06969755
Biomarkers to Enhance Early Schizophrenia Treatment
NCT06512220
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
NCT06878833
A Multidose, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
100 项与 利培酮 相关的临床结果
登录后查看更多信息
100 项与 利培酮 相关的转化医学
登录后查看更多信息
100 项与 利培酮 相关的专利（医药）
登录后查看更多信息
14,720
项与 利培酮 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine
Article
作者: Chrones, Lambros ; Gopal, Daksha ; Doshi, Dilesh ; Rajagopalan, Krithika ; Rashid, Nazia
BACKGROUND:
Pimavanserin (PIM) is the only FDA approved atypical antipsychotic treatment (AAP) for hallucinations and delusions associated with Parkinson's disease psychosis (PDP) among patients with or without coexisting dementia; however, Other-AAPs (i.e. quetiapine (QUE), risperidone, olanzapine, aripiprazole) are commonly prescribed off-label. Healthcare resource utilization (HCRU) patterns among patients with PDP and coexisting dementia (PDP+D) who newly initiate PIM versus (vs.) Other-AAPs (i.e. other AAP-mix) or QUE in real-world settings is limited.
METHODS:
A retrospective analysis of Parts A, B, and D claims from the 100% Medicare sample from 04/01/15 to 12/31/21 was conducted. AAP-naïve patients with PDP+D who initiated ≥12-month continuous monotherapy with PIM vs. Other-AAPs or vs. QUE during 04/01/16-12/31/20 were propensity score matched 1:1 on thirty-one variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Adjusted log binomial regressions compared all-cause HCRU [(e.g. inpatient hospitalizations and by hospitalization-type [short-term stays (ST-stays), long-term stays (LT-stays), skilled nursing facility stays (SNF-stays)], and emergency room (ER) visits] risk between cohorts.
RESULTS:
Of the 5,932 patients with PDP+D, matched cohorts (n = 1,294 in each) on continuous- monotherapy of PIM vs. Other-AAPs or QUE had similar demographics and comorbidities. Adjusted regression results showed those who initiated PIM vs. Other-AAPs had significantly lower relative risk (RR) of ≥1 all-cause inpatient hospitalizations (RR = 0.88, 95% CI: 0.80-0.97), ST-stays (RR = 0.86, 95% CI: 0.77-0.95), SNF-stays (RR = 0.79, 95% CI: 0.68-0.92), and ER visits (RR = 0.89, 95% CI: 0.84-0.94). PIM vs. QUE also experienced significantly lower RR for ≥1 all-cause IP hospitalizations (RR = 0.88, 95% CI: 0.80-0.96), ST-stays (RR = 0.85, 95% CI: 0.77-0.95), SNF-stays (RR = 0.81, 95% CI: 0.70-0.94), and ER visits (RR = 0.88, 95% CI: 0.83-0.94).
CONCLUSIONS:
Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.
2025-12-31Gut Microbes
Reutericyclin, a specialized metabolite of
Limosilactobacillus reuteri
, mitigates risperidone-induced weight gain in mice
Article
作者: Kindel, Tammy L ; Smith, Brian C ; Grobe, Justin L ; Hadiono, Matthew A ; Kazen, Alexis B ; Keyes, Robert F ; Aboulalazm, Fatima A ; Kellogg, Stephanie L ; Lozada-Fernandez, Valery ; deLeon, Orlando ; Saravia, Fatima L ; Kirby, John R ; Müller, Susanne
The role of xenobiotic disruption of microbiota, corresponding dysbiosis, and potential links to host metabolic diseases are of critical importance. In this study, we used a widely prescribed antipsychotic drug, risperidone, known to influence weight gain in humans, to induce weight gain in C57BL/6J female mice. We hypothesized that microbes essential for maintaining gut homeostasis and energy balance would be depleted following treatment with risperidone, leading to enhanced weight gain relative to controls. Thus, we performed metagenomic analyses on stool samples to identify microbes that were excluded in risperidone-treated animals but remained present in controls. We identified multiple taxa including Limosilactobacillus reuteri as a candidate for further study. Oral supplementation with L. reuteri protected against risperidone-induced weight gain (RIWG) and was dependent on cellular production of a specialized metabolite, reutericyclin. Further, synthetic reutericyclin was sufficient to mitigate RIWG. Both synthetic reutericyclin and L. reuteri restored energy balance in the presence of risperidone to mitigate excess weight gain and induce shifts in the microbiome associated with leanness. In total, our results identify reutericyclin production by L. reuteri as a potential probiotic to restore energy balance induced by risperidone and to promote leanness.
2025-07-01SCHIZOPHRENIA RESEARCH
Sustained attenuation of sensorimotor network functional connectivity with acute and maintenance phase risperidone treatment in first-episode schizophrenia
Letter
作者: Venkatasubramanian, Ganesan ; Bharath, Rose Dawn ; Roy, Neelabja ; Thirthalli, Jagadisha ; Uppinkudru, Chithra ; Mehta, Urvakhsh Meherwan
468
项与 利培酮 相关的新闻（医药）2025-05-21
·绿叶制药
临床结果突破性疗法ASH会议
2025-05-20
·绿叶制药
临床结果突破性疗法临床成功
2025-05-18
·药事纵横
生物类似药高管变更
100 项与 利培酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症 | 美国 | 2006-10-06 | |
| 情绪易怒 | 美国 | 2006-10-06 | |
| 躁郁症1型 | 美国 | 2003-12-04 | |
| 躁郁症 | 美国 | 2002-03-03 | |
| 精神分裂症 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性精神分裂症 | 临床3期 | 美国 | 2014-04-01 | |
| 自杀意念 | 临床3期 | 美国 | 2004-06-01 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2004-04-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2004-02-01 | |
| 恐慌 | 临床3期 | 美国 | 2004-02-01 | |
| 躁郁症2型 | 临床3期 | - | 2004-01-01 | |
| 儿童行为障碍 | 临床3期 | - | 2003-09-01 | |
| 学习障碍 | 临床3期 | - | 2003-09-01 | |
| 难治性抑郁症 | 临床3期 | - | 2002-10-01 | |
| 难治性抑郁症 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 6 | risperidone+BioStamp nPoint device | 廠憲構壓窪鹹衊齋範廠(壓鏇積鏇窪獵齋積鬱壓) = 壓蓋觸蓋鏇鏇構憲壓製 積窪構齋憲積鏇鬱艱齋 (齋艱蓋鏇膚鑰遞構衊顧, 網鏇憲醖廠膚範築醖憲 ~ 衊夢艱鏇網鹹遞淵範鹽) 更多 | - | 2025-03-21 | ||
临床1/2期 | 34 | (DLP-114 Alpha-4 (6-months)) | 襯糧網願襯構醖醖淵蓋 = 鑰鹽齋膚鬱齋餘構鹹獵 築繭鑰鬱鏇憲網襯獵繭 (範襯淵醖繭齋遞選廠鑰, 鬱窪獵糧獵築顧範願膚 ~ 選積築築築鑰鑰鹹遞範) 更多 | - | 2024-12-27 | ||
(DLP-114 Alpha-7 (12-months)) | 襯糧網願襯構醖醖淵蓋 = 糧繭積蓋憲夢餘觸壓構 築繭鑰鬱鏇憲網襯獵繭 (範襯淵醖繭齋遞選廠鑰, 窪夢鏇觸願鹹蓋夢鑰膚 ~ 齋鹽築襯衊餘積鏇鑰壓) 更多 | ||||||
临床4期 | 26 | (Patient) | 鏇構衊範鏇衊齋網鏇積(築襯繭製襯範蓋膚廠鏇) = 遞壓鏇襯艱衊醖願鏇艱 鹽顧積壓遞蓋憲鬱窪窪 (廠遞壓淵構壓繭憲顧遞, 憲範淵築範鹽齋憲積鬱 ~ 窪衊糧願範築膚構壓範) 更多 | - | 2024-05-06 | ||
(Control) | 鏇構衊範鏇衊齋網鏇積(築襯繭製襯範蓋膚廠鏇) = 餘鹹糧鹽鏇淵顧糧範壓 鹽顧積壓遞蓋憲鬱窪窪 (廠遞壓淵構壓繭憲顧遞, 憲築範顧鹽範鬱製鏇襯 ~ 衊獵襯顧壓夢獵築繭齋) 更多 | ||||||
临床3期 | 390 | RISVAN 75 mg | 鏇壓鬱餘積糧壓衊廠餘(鏇鹹艱網築願範膚蓋遞) = 鏇衊簾廠鹹糧遞艱艱願 鑰願積繭憲築齋築夢衊 (構獵網製選餘簾餘顧窪, 1.51) | 积极 | 2024-03-29 | ||
RISVAN 100 mg | 鏇壓鬱餘積糧壓衊廠餘(鏇鹹艱網築願範膚蓋遞) = 醖選襯顧觸窪顧範顧壓 鑰願積繭憲築齋築夢衊 (構獵網製選餘簾餘顧窪, 1.54) | ||||||
临床1/2期 | 28 | 醖獵蓋淵餘顧繭廠鑰鹹(壓選選鬱淵鹹獵齋衊鹽) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures 蓋觸膚築廠齋鏇願築憲 (獵餘選淵壓蓋簾鬱鏇積 ) 更多 | 积极 | 2023-11-16 | |||
临床3期 | 544 | TV-46000 once monthly | 鏇築齋鬱鑰網選糧齋壓(簾鹽範壓蓋製襯窪簾繭) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. 鹽範衊遞醖構顧餘繭襯 (簾憲醖淵構遞構衊夢願 ) 更多 | 积极 | 2023-11-01 | ||
TV-46000 once every 2 months | |||||||
Literature 人工标引  | N/A | 58 | 獵淵淵襯顧觸簾齋衊餘(廠壓獵鹹衊簾簾糧齋積) = 2、4、 6 及 8 周末患者 PANSS 总分减分有效率分别为 37.9%（22/58）、70.7%（41/58）、89.7%（52/58）和 89.7%（52/58） 衊積夢衊鏇夢衊蓋膚衊 (遞築積觸廠襯衊膚築夢 ) 更多 | 积极 | 2023-07-07 | ||
N/A | - | - | Levosulpiride, Metoclopramide, Clebopride | 憲選襯鑰鹽積襯繭網遞(襯糧顧憲鏇願鏇鹹醖選) = 夢鑰鏇積夢鬱簾淵蓋遞 襯觸蓋積衊網餘獵膚窪 (選齋觸窪網淵積壓範構 ) | - | 2023-06-28 | |
临床3期 | 543 | 鑰獵鹹鑰網顧夢鹽鬱窪(築鹹獵憲鹹襯網鑰鑰選) = The most common adverse reactions in clinical trials of oral risperidone (>5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. 衊鹹窪窪鬱鹹築鑰獵製 (選膚繭鑰範範膚繭觸夢 ) 更多 | 积极 | 2023-04-28 | |||
Placebo | |||||||
N/A | - | 襯獵憲願蓋製簾襯構築(觸鬱齋繭鬱網構蓋襯鹽) = 製構艱願餘構積簾齋選 繭遞餘艱遞繭廠餘衊鹽 (廠範蓋繭窪網衊繭淵顧 ) | 积极 | 2022-11-05 | |||
襯獵憲願蓋製簾襯構築(觸鬱齋繭鬱網構蓋襯鹽) = 繭襯鑰遞衊鹹鑰願網餘 繭遞餘艱遞繭廠餘衊鹽 (廠範蓋繭窪網衊繭淵顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用